By AACR Associate Member Council members, 2025-2026 Attending the AACR Annual Meeting is a defining moment for early‑career researchers...
After Craig Schumpert learned he had lung cancer that had spread to his brain, bones, and lymph nodes, he...
For most solid tumors, traditional biopsies are the gold standard for diagnosing cancer and assessing molecular characteristics that may...
With the August 2020 U.S. Food and Drug Administration approvals of the Guardant 360 CDx and FoundationOne Liquid CDx...
Circulating tumor DNA (ctDNA) was first detected over 30 years ago, but its potential uses for cancer diagnosis and...
Liquid biopsies, noninvasive tests performed on biofluids to detect genetic alterations in tumors, are a recent revolution in the...
What does a naked mole rat, a nuclear exporter that “moonlights” as a chromatin regulator, and the combined power...
Learn how liquid biopsy could be used to detect cancer and guide treatment as researchers work to develop more...
In the span of a decade, the idea that tumor-derived molecules circulating in the bloodstream and other body fluids...
Cancer is the second leading cause of death globally, accounting for nearly 10 million deaths each year. Late-stage diagnosis is a major contributor of cancer-related mortality, as...
The second day of the AACR Virtual Annual Meeting II began with a clinical trials plenary session. Two of the session’s presentations, which focused on immunotherapy clinical...